Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Psoriasis in children: Management of chronic plaque psoriasis

Amy S Paller, MD
Emily Broun Lund, MD
Section Editors
Kristina Callis Duffin, MD
Moise L Levy, MD
Deputy Editor
Abena O Ofori, MD


Psoriasis is a systemic immune-mediated disease that can negatively impact the quality of life of affected children and their families (picture 1A-F). In most children, psoriasis can be adequately treated with topical medications. However, children with moderate to severe psoriasis often require phototherapy or systemic therapy.

Although many of the therapies commonly administered for psoriasis in children and adults are similar, high-quality efficacy and safety trials to guide the best approach to psoriasis in children are more limited. As a result, the development of guidelines for the treatment of pediatric psoriasis is challenging. In clinical practice, consideration of patient-specific factors, such as patient age, severity of disease, comorbidities, and tolerance of the risks and side effects of specific medications, guides the approach to treatment.

The management of chronic plaque psoriasis, the most common clinical variant of psoriasis in children, will be reviewed here. The diagnosis of psoriasis in children and the approach to treatment of other clinical variants of psoriasis and psoriatic arthritis are reviewed separately.

(See "Psoriasis in children: Epidemiology, clinical manifestations, and diagnosis".)

(See "Guttate psoriasis".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Nov 03, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Stein Gold L, Jackson JM, Knuckles ML, Weiss JS. Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05. J Drugs Dermatol 2016; 15:334.
  2. Sofen H, Hudson CP, Cook-Bolden FE, et al. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. J Drugs Dermatol 2011; 10:885.
  3. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; :CD005028.
  4. Kimball AB, Gold MH, Zib B, et al. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol 2008; 59:448.
  5. Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997; 36:203.
  6. Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996; 135:390.
  7. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999; 16:321.
  8. Diluvio L, Campione E, Paternò EJ, et al. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol 2007; 24:332.
  9. Kortuem KR, Davis MD, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol 2010; 27:518.
  10. Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol 2009; 61:294.
  11. Oostveen AM, Beulens CA, van de Kerkhof PC, et al. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. Br J Dermatol 2014; 170:454.
  12. de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology 2010; 220:329.
  13. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62:1013.
  14. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24:76.
  15. Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 2006; 12:7.
  16. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 2004; 18:742.
  17. Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. Br J Dermatol 2014; 171:1470.
  18. Oostveen AM, de Jong EM, Donders AR, et al. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice. J Eur Acad Dermatol Venereol 2015; 29:1193.
  19. Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol 2015; 32:28.
  20. Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390:40.
  21. Garber C, Creighton-Smith M, Sorensen EP, et al. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review. J Drugs Dermatol 2015; 14:881.
  22. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014; 170:274.
  23. Signorovitch JE, Betts KA, Yan YS, et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol 2015; 172:504.
  24. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73:594.
  25. van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatolog Treat 2015; 26:406.
  26. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008; 25:184.
  27. Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009; 34:295.
  28. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833.
  29. Crall CS, Rork JF, Delano S, Huang JT. Phototherapy in children: Considerations and indications. Clin Dermatol 2016; 34:633.
  30. Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol 2011; 25:727.
  31. Zamberk P, Velázquez D, Campos M, et al. Paediatric psoriasis--narrowband UVB treatment. J Eur Acad Dermatol Venereol 2010; 24:415.
  32. Tan E, Lim D, Rademaker M. Narrowband UVB phototherapy in children: A New Zealand experience. Australas J Dermatol 2010; 51:268.
  33. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241.
  34. Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab versus methotrexate treatment in pediatric patients with severe chronic plaque psoriasis: results from the 16-week randomized, double-blind period of a phase 3 study. Abstract #2970552, 23rd World Congress of Dermatology, Vancouver, Canada, 2015.
  35. Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63:762.
  36. van Geel MJ, Mul K, de Jager ME, et al. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol 2015; 29:425.
  37. Di Lernia V, Stingeni L, Boccaletti V, et al. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. J Dermatolog Treat 2016; 27:395.
  38. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45:649.
  39. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003; 49:171.
  40. Di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis. Pediatr Dermatol 2016; 33:530.
  41. Charbit L, Mahé E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol 2016; 174:1118.
  42. Reich K, Hartl C, Gambichler T, Zschocke I. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges 2016; 14:50.
  43. van Geel MJ, van de Kerkhof PC, Oostveen AM, et al. Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series. J Dermatolog Treat 2016; 27:214.
  44. van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368:1658.
  45. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368:1657.
  46. Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 2017; 264:1155.
  47. Osier E, Wang AS, Tollefson MM, et al. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol 2017; 153:698.